ATE316969T1 - Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) - Google Patents
Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)Info
- Publication number
- ATE316969T1 ATE316969T1 AT99953833T AT99953833T ATE316969T1 AT E316969 T1 ATE316969 T1 AT E316969T1 AT 99953833 T AT99953833 T AT 99953833T AT 99953833 T AT99953833 T AT 99953833T AT E316969 T1 ATE316969 T1 AT E316969T1
- Authority
- AT
- Austria
- Prior art keywords
- dopamine
- receptor modulators
- antipsychotic agents
- derivatives usable
- tetrahydrobenzazepine derivatives
- Prior art date
Links
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical class N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 title 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- 239000000164 antipsychotic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821976.9A GB9821976D0 (en) | 1998-10-08 | 1998-10-08 | Compounds |
| GBGB9824340.5A GB9824340D0 (en) | 1998-11-06 | 1998-11-06 | Compounds |
| GBGB9910711.2A GB9910711D0 (en) | 1999-05-07 | 1999-05-07 | Compounds |
| GBGB9918032.5A GB9918032D0 (en) | 1999-07-30 | 1999-07-30 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE316969T1 true ATE316969T1 (de) | 2006-02-15 |
Family
ID=27451837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99953833T ATE316969T1 (de) | 1998-10-08 | 1999-10-06 | Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6605607B1 (de) |
| EP (1) | EP1119563B1 (de) |
| JP (1) | JP2002527433A (de) |
| KR (1) | KR20010085898A (de) |
| CN (1) | CN1329609A (de) |
| AP (1) | AP2001002114A0 (de) |
| AR (1) | AR023681A1 (de) |
| AT (1) | ATE316969T1 (de) |
| AU (1) | AU761018B2 (de) |
| BG (1) | BG105467A (de) |
| BR (1) | BR9914370A (de) |
| CA (1) | CA2346689A1 (de) |
| CO (1) | CO5140073A1 (de) |
| CZ (1) | CZ20011270A3 (de) |
| DE (1) | DE69929704T2 (de) |
| EA (1) | EA200100428A1 (de) |
| ES (1) | ES2255311T3 (de) |
| HK (1) | HK1038745A1 (de) |
| HU (1) | HUP0104280A3 (de) |
| ID (1) | ID28385A (de) |
| IL (1) | IL142388A0 (de) |
| MA (1) | MA26696A1 (de) |
| NO (1) | NO20011745L (de) |
| NZ (1) | NZ511018A (de) |
| OA (1) | OA11663A (de) |
| PE (1) | PE20001088A1 (de) |
| PL (1) | PL347237A1 (de) |
| SK (1) | SK4782001A3 (de) |
| TR (1) | TR200101025T2 (de) |
| WO (1) | WO2000021951A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| ID28385A (id) | 1998-10-08 | 2001-05-17 | Smithkline Beecham Plc | Turunan-turunan tetrahidrobenzazepina yang berguna sebagai modulator reseptor d3 dopamina (bahan antipsikotik) |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| PL362992A1 (en) * | 2000-11-14 | 2004-11-15 | Smithkline Beecham P.L.C. | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| WO2002051232A2 (en) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| EP1456178A1 (de) * | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepinderivate als modulatoren des dopaminrezeptors und deren verwendung in der behandlung von krankheiten des zentralen nervensystems |
| WO2003068732A2 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds |
| WO2003068749A1 (en) | 2002-02-15 | 2003-08-21 | Glaxo Group Limited | Vanilloid receptor modulators |
| GB0224083D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| ES2401319T3 (es) | 2002-12-20 | 2013-04-18 | Glaxo Group Limited | Nuevo derivado de benzazepina |
| HUE055434T2 (hu) | 2003-04-11 | 2021-11-29 | Ptc Therapeutics Inc | 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére |
| US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| JP4982184B2 (ja) | 2003-12-18 | 2012-07-25 | アボット ゲーエムベーハー ウント カンパニー カーゲー | テトラヒドロベンズアゼピンおよびドーパミンｄ３レセプターの調節におけるこれらの使用 |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| EP1725238A4 (de) * | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | M 3 muscarinacetylcholin-rezeptor-antagonisten |
| EP1725240A4 (de) * | 2004-03-17 | 2009-03-25 | Glaxo Group Ltd | Antagonisten des muskarinen acetylcholinrezeptors |
| EP1725241A4 (de) * | 2004-03-17 | 2009-03-25 | Glaxo Group Ltd | M3 muscarinacetylcholin-rezeptor-antagonisten |
| KR20080064953A (ko) * | 2005-10-13 | 2008-07-10 | 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 | 항균 활성을 갖는 5-퀴놀린 유도체 |
| JP6419826B2 (ja) | 2013-12-13 | 2018-11-07 | ピエール、ファーブル、メディカマン | 自閉症スペクトラム障害の治療のためのドーパミンｄ３受容体拮抗薬としてのクロモン誘導体 |
| CN106455571A (zh) | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
| CN108348527A (zh) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
| MA45614B1 (fr) | 2017-03-20 | 2020-04-30 | Forma Therapeutics Inc | Compositions de pyrrolopyrrole en tant qu'activateurs de la pyruvate kinase (pkr) |
| CN111433201B (zh) * | 2017-12-21 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 苯并氮杂䓬衍生物、其制备方法及其在医药上的应用 |
| KR20200112910A (ko) | 2018-01-26 | 2020-10-05 | 시오노기 앤드 컴파니, 리미티드 | 도파민 d3 수용체 길항 작용을 갖는 축환 화합물 |
| CN110498768A (zh) * | 2018-05-17 | 2019-11-26 | 上海中泽医药科技有限公司 | 庚嗪类化合物及其在制备抗精神分裂症药物中的应用 |
| CN113166060B (zh) | 2018-09-19 | 2024-01-09 | 诺沃挪第克健康护理股份公司 | 用丙酮酸激酶激活化合物治疗镰状细胞病 |
| EP3852791B1 (de) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Aktivierung von pyruvatkinase r |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CA3151612A1 (en) | 2019-09-19 | 2021-03-25 | George P. Luke | Pyruvate kinase r (pkr) activating compositions |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| US4220778A (en) | 1978-10-30 | 1980-09-02 | G. D. Searle & Co. | 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof |
| IL63918A0 (en) | 1980-10-17 | 1981-12-31 | Pennwalt Corp | N-(amino(or hydroxy)phenethyl)-1,2,3,4-tetrahydroisoquinolines,their preparation and pharmaceutical compositions containing them |
| ZA816903B (en) | 1980-10-17 | 1983-02-23 | Pennwalt Corp | N-(amino(or hydroxy)-1,2,3,4,-tetrahydroisoquinolines, precursors thereof, and methods of preparation |
| FR2618149B1 (fr) | 1987-07-16 | 1989-09-22 | Synthelabo | Derives de n-aminoalkyl n-phenyl arylamides, leur preparation et leur application en therapeutique |
| IL89156A (en) | 1988-07-12 | 1993-05-13 | Synthelabo | Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics |
| US5217977A (en) | 1989-02-28 | 1993-06-08 | Imperial Chemical Industries Plc | Heterocyclic cycloalkanes |
| US5047406A (en) | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
| US5633376A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
| US5681956A (en) | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| SG45403A1 (en) | 1991-01-11 | 1998-01-16 | Glaxo Lab Sa | Acridine derivatives |
| WO1993003025A1 (en) | 1991-08-09 | 1993-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Thiophene compound |
| US5532240A (en) | 1991-12-26 | 1996-07-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Condensed thiophene compound and pharmaceutical use thereof |
| CA2104371A1 (en) | 1991-12-26 | 1993-06-27 | Tohru Nakao | Condensed thiophene compound and pharmaceutical use thereof |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| JP2718830B2 (ja) | 1992-07-10 | 1998-02-25 | ラボラトワール、グラクソ、ソシエテ、アノニム | アニリド誘導体 |
| DE69321126D1 (de) | 1992-08-06 | 1998-10-22 | Smithkline Beecham Plc | 5-(2-oxyphenyl)-pyrrol-derivate als dopamin-d3-rezeptor-antagonisten |
| US5294621A (en) | 1992-10-07 | 1994-03-15 | Ortho Pharmaceutical Corporation | Thieno tetrahydropyridines useful as class III antiarrhythmic agents |
| GB9305644D0 (en) * | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| GB9307400D0 (en) | 1993-04-08 | 1993-06-02 | Smithkline Beecham Plc | Compounds |
| FR2706895A1 (en) | 1993-06-22 | 1994-12-30 | Synthelabo | Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics |
| JP2959615B2 (ja) | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
| AU7186994A (en) | 1993-06-25 | 1995-01-17 | Smithkline Beecham Plc | Phenyrrole derivatives and their use as dopamine d3 antagonists |
| GB9315800D0 (en) | 1993-07-30 | 1993-09-15 | Smithkline Beecham Plc | Compounds |
| GB9315801D0 (en) | 1993-07-30 | 1993-09-15 | Smithkline Beecham Plc | Compounds |
| HUT75876A (en) | 1993-08-12 | 1997-05-28 | Astra Ab | Amidine derivatives with nitric oxide synthetase activities, pharmaceutical compositions containing them and process for their preparation |
| AU7665694A (en) | 1993-09-21 | 1995-04-10 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| GB9320855D0 (en) | 1993-10-09 | 1993-12-01 | Smithkline Beecham Plc | Compounds |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| GB9325827D0 (en) | 1993-12-17 | 1994-02-23 | Smithkline Beecham Plc | Compounds |
| GB9402197D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Compounds |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9403199D0 (en) | 1994-02-19 | 1994-04-13 | Smithkline Beecham Plc | Compounds |
| US5686482A (en) | 1994-04-28 | 1997-11-11 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl) benzamide derivative |
| US5414010A (en) | 1994-05-10 | 1995-05-09 | Warner-Lambert Company | Dimeric benzimidazoles as central nervous system agents |
| DE4425143A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
| DE4425144A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
| DE4425145A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung von Thiazol- und Thiadiazolverbindungen |
| GB9418912D0 (en) | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
| CZ104197A3 (en) | 1994-10-05 | 1997-09-17 | Glaxo Wellcome Inc | Pharmaceutical preparation |
| US5478934A (en) | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
| JP2941950B2 (ja) | 1994-11-23 | 1999-08-30 | ニューロゲン コーポレイション | 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド |
| GB9426090D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| GB9426071D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| EP0809641A1 (de) | 1995-02-15 | 1997-12-03 | Neurogen Corporation | Verbrückte 4-phenyl-2-aminomethylimidazole: neue dopaminrezeptorsubtyp-spezifische liganden |
| AU5147196A (en) | 1995-03-27 | 1996-10-16 | Smithkline Beecham Plc | Bicyclic amine derivatives and their use as anti-psychotic a gents |
| GB9512129D0 (en) | 1995-06-15 | 1995-08-16 | Smithkline Beecham Plc | Compounds |
| US5977110A (en) | 1995-09-22 | 1999-11-02 | Warner-Lambert Company | Substituted cyclohexylamines as central nervous systems agents |
| FR2741074B1 (fr) | 1995-11-09 | 1997-12-19 | Adir | Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
| AU1597197A (en) | 1996-02-01 | 1997-08-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thienoquinolines |
| EP0887340A4 (de) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | Chemische verbindungen und deren pharmazeutische verwendungen |
| JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
| US5710274A (en) | 1996-02-28 | 1998-01-20 | Neurogen Corporation | N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands |
| US5763609A (en) | 1996-03-21 | 1998-06-09 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands |
| US5703237A (en) | 1996-04-18 | 1997-12-30 | Neurogen Corporation | N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands |
| US5688950A (en) | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
| CZ363298A3 (cs) | 1996-05-11 | 1999-06-16 | Smithkline Beecham P. L. C. | Tetrahydroizochinolinové deriváty jako modulátory receptorů dopaminu D3 |
| GB9612153D0 (en) | 1996-06-11 | 1996-08-14 | Smithkline Beecham Plc | Compounds |
| AU4204697A (en) * | 1996-08-14 | 1998-03-06 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives and their pharmaceutical use |
| WO1998007421A1 (en) | 1996-08-16 | 1998-02-26 | Ishihara Sangyo Kaisha, Ltd. | Medicinal composition |
| BR9714364A (pt) | 1996-11-27 | 2000-03-21 | Pfizer | Amidas inibidoras da secreção de apo b/mtp |
| FR2761985B1 (fr) | 1997-04-10 | 1999-05-21 | Adir | Nouveaux composes amines du 6,7,8,9-tetrahydro-cyclopenta[a] naphtalene et du 2,3-dihydro-cyclopenta[e]indene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU7260398A (en) | 1997-04-28 | 1998-11-24 | University Of British Columbia, The | Method and composition for modulating amyloidosis |
| GB9708694D0 (en) | 1997-04-30 | 1997-06-18 | Smithkline Beecham Plc | Compounds |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| JP2002501506A (ja) * | 1997-05-03 | 2002-01-15 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ドーパミンｄ▲下３▼受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体 |
| GB9709303D0 (en) | 1997-05-09 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| GB9710612D0 (en) | 1997-05-23 | 1997-07-16 | Glaxo Group Ltd | Synthesis of acridine derivatives |
| DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| ID28385A (id) | 1998-10-08 | 2001-05-17 | Smithkline Beecham Plc | Turunan-turunan tetrahidrobenzazepina yang berguna sebagai modulator reseptor d3 dopamina (bahan antipsikotik) |
| GB9821977D0 (en) | 1998-10-08 | 1998-12-02 | Smithkline Beecham Plc | Compounds |
| AR022228A1 (es) | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion |
-
1999
- 1999-10-06 ID IDW20010785A patent/ID28385A/id unknown
- 1999-10-06 JP JP2000575857A patent/JP2002527433A/ja not_active Withdrawn
- 1999-10-06 PE PE1999001015A patent/PE20001088A1/es not_active Application Discontinuation
- 1999-10-06 EP EP99953833A patent/EP1119563B1/de not_active Expired - Lifetime
- 1999-10-06 IL IL14238899A patent/IL142388A0/xx unknown
- 1999-10-06 AP APAP/P/2001/002114A patent/AP2001002114A0/en unknown
- 1999-10-06 AT AT99953833T patent/ATE316969T1/de not_active IP Right Cessation
- 1999-10-06 CO CO99063348A patent/CO5140073A1/es unknown
- 1999-10-06 US US09/806,902 patent/US6605607B1/en not_active Expired - Fee Related
- 1999-10-06 OA OA1200100090A patent/OA11663A/en unknown
- 1999-10-06 WO PCT/EP1999/007763 patent/WO2000021951A1/en not_active Ceased
- 1999-10-06 DE DE69929704T patent/DE69929704T2/de not_active Expired - Fee Related
- 1999-10-06 CZ CZ20011270A patent/CZ20011270A3/cs unknown
- 1999-10-06 NZ NZ511018A patent/NZ511018A/en unknown
- 1999-10-06 CA CA002346689A patent/CA2346689A1/en not_active Abandoned
- 1999-10-06 CN CN99814062A patent/CN1329609A/zh active Pending
- 1999-10-06 MA MA25809A patent/MA26696A1/fr unknown
- 1999-10-06 KR KR1020017004442A patent/KR20010085898A/ko not_active Withdrawn
- 1999-10-06 SK SK478-2001A patent/SK4782001A3/sk unknown
- 1999-10-06 HU HU0104280A patent/HUP0104280A3/hu unknown
- 1999-10-06 HK HK02100150.4A patent/HK1038745A1/zh unknown
- 1999-10-06 EA EA200100428A patent/EA200100428A1/ru unknown
- 1999-10-06 PL PL99347237A patent/PL347237A1/xx not_active Application Discontinuation
- 1999-10-06 AR ARP990105055A patent/AR023681A1/es not_active Application Discontinuation
- 1999-10-06 AU AU10381/00A patent/AU761018B2/en not_active Ceased
- 1999-10-06 BR BR9914370-4A patent/BR9914370A/pt not_active IP Right Cessation
- 1999-10-06 TR TR2001/01025T patent/TR200101025T2/xx unknown
- 1999-10-06 ES ES99953833T patent/ES2255311T3/es not_active Expired - Lifetime
-
2001
- 2001-04-06 NO NO20011745A patent/NO20011745L/no not_active Application Discontinuation
- 2001-04-24 BG BG105467A patent/BG105467A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1038100A (en) | 2000-05-01 |
| EP1119563A1 (de) | 2001-08-01 |
| PE20001088A1 (es) | 2000-12-02 |
| ID28385A (id) | 2001-05-17 |
| NO20011745D0 (no) | 2001-04-06 |
| OA11663A (en) | 2004-12-08 |
| AP2001002114A0 (en) | 2001-06-30 |
| MA26696A1 (fr) | 2004-12-20 |
| TR200101025T2 (tr) | 2001-09-21 |
| SK4782001A3 (en) | 2001-11-06 |
| CA2346689A1 (en) | 2000-04-20 |
| DE69929704D1 (de) | 2006-04-13 |
| HUP0104280A3 (en) | 2002-07-29 |
| IL142388A0 (en) | 2002-03-10 |
| AU761018B2 (en) | 2003-05-29 |
| CN1329609A (zh) | 2002-01-02 |
| PL347237A1 (en) | 2002-03-25 |
| KR20010085898A (ko) | 2001-09-07 |
| JP2002527433A (ja) | 2002-08-27 |
| AR023681A1 (es) | 2002-09-04 |
| HUP0104280A2 (hu) | 2002-03-28 |
| EP1119563B1 (de) | 2006-02-01 |
| CZ20011270A3 (cs) | 2001-09-12 |
| BG105467A (en) | 2001-11-30 |
| BR9914370A (pt) | 2001-11-27 |
| NO20011745L (no) | 2001-06-06 |
| CO5140073A1 (es) | 2002-03-22 |
| HK1038745A1 (zh) | 2002-03-28 |
| US6605607B1 (en) | 2003-08-12 |
| WO2000021951A1 (en) | 2000-04-20 |
| ES2255311T3 (es) | 2006-06-16 |
| NZ511018A (en) | 2003-09-26 |
| DE69929704T2 (de) | 2006-07-20 |
| EA200100428A1 (ru) | 2001-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE316969T1 (de) | Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) | |
| DE60132235D1 (de) | Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) | |
| ATE227716T1 (de) | 2-substituierte-1-piperidyl- benzimidazolverbindungen als orl1 rezeptor agonisten | |
| ATE268776T1 (de) | Benzodiazepinderivate als gaba-a- rezeptormodulatoren | |
| PT1049689E (pt) | Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1 | |
| ATE260914T1 (de) | Triazolyltropanderivate als ccr5-modulatoren | |
| ATE344254T1 (de) | 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren | |
| NO20015272L (no) | Glukokortikoid reseptor modulatorer | |
| NO995338D0 (no) | Tetrahydroisokinolinderivater som modulatorer for dopamin-D3-reseptorer | |
| ATE283857T1 (de) | Imidazo(1,5-aöpyrimido)5,4-döbenz azepinderivate als gaba-a-rezeptormodulatoren | |
| NO20013456D0 (no) | Funksjonaliserte heterocykler som chemokin-reseptor- modulatorer | |
| DE69841138D1 (de) | Imidazolderivate als mdr-modulatoren | |
| NO20004261L (no) | 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister | |
| NO994106L (no) | Oksazolidiner som 5-HT2A-antagonister | |
| ATE277901T1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
| ATE282606T1 (de) | Indolderivate als serotonergische mittel | |
| DE69703242D1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten | |
| DE60003072D1 (de) | Thiazolidindion-derivate als antidiabetika | |
| AU2003227919A1 (en) | Dopamine receptor modulators as antipsychotic agents | |
| ATE236150T1 (de) | (4-piperidinyl)-1h-2-benzopyran derivate verwendbar als antipsychotische mittel | |
| DE69717449D1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten | |
| NO20012939L (no) | Substituerte, heterosykliske asyl-tripeptider for bruk som trombinreseptormodulatorer | |
| DE60012953D1 (de) | 3-amino-2-phenylpiperidinderivate als substanz p antagonisten | |
| EP1124552A4 (de) | Chrysen-derivate als antitumormittel | |
| HK1061388A (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |